OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press62210.17650/1818-8346-2007-0-2-4-9DIAGNOSIS OF HEMATOLOGIC MALIGNANCIESДИАГНОСТИКА ГЕМОБЛАСТОЗОВDifferential diagnosis of non-Hodgkin's B-cell lymphomasДифференциальная диагностика неходжкинских В-клеточных лимфомKovriginaA. M.КовригинаА. М.
Russian Federation

Moscow

Москва

ProbatovaN. A.ПробатоваН. А.
Russian Federation

Moscow

Москва

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesРОНЦ им. Н.Н. Блохина РАМН2305200724922112022221120222007https://oncohematology.abvpress.ru/ongm/article/view/622

This article reviews the problems of morphological and immunohistochemical diagnosis of non-Hodgkin's B-cell lymphomas. We compared immunophenotype of B-cell lymphoid neoplasms and their «normal cell» analogs taking into account 4 stages during B-cell differentiation: bone marrow B-cell precursors, mature naive B cells, B cells with follicular differentiation, and postfollicular B cells. We proposed an algorithm of immunohistochemical differential diagnosis.

В статье рассматриваются вопросы морфологической и иммуногистохимической диагностики неходжкинских В-клеточных лимфом. Проводится сопоставление иммунофенотипа В-клеточных лимфоидных опухолей, их «нормальных» клеточных аналогов с учетом четырех этапов В-клеточной дифференцировки: В-клетки-предшественницы костного мозга, зрелой наивной В-клетки, В-клетки с фолликулярной дифференцировкой, постфолликулярной В-клетки. Предложены алгоритмы иммуногистохимической дифференциальной диагностики.

non-Hodgkin's lymphomasB-cell lymphomasdiagnosismorphologyimmunophenotypeнеходжкинские лимфомыВ-клеточные лимфыдиагностикаморфологияиммунофенотип1. Jaffe E.S., Harris N., Vardiman J. et al. WHO Classification of tumors. Tumours of haematopoietic and lymphoid tissues. Pathology and Genetics. Lyon, IARC Press; 2001.Jaffe E.S., Harris N., Vardiman J. et al. WHO Classification of tumors. Tumours of haematopoietic and lymphoid tissues. Pathology and Genetics. Lyon, IARC Press; 2001.2. Dong H.Y., Liu Z., Browne P. et al. B cell malignancies lacking common B cell antigens consistently express PAX-5. Mod Pathol 2004;17:246A.Dong H.Y., Liu Z., Browne P. et al. B cell malignancies lacking common B cell antigens consistently express PAX-5. Mod Pathol 2004;17:246A.3. Horcher M., Souabni A., Busslinger M. Pax 5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity 2001;14:779—90.Horcher M., Souabni A., Busslinger M. Pax 5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity 2001;14:779—90.4. Rolink A.G., Schaniel C., Andersson J. et al. Selection events operating at various stages in B-cell development. Curr Opin Immunol 2001;13:202—7.Rolink A.G., Schaniel C., Andersson J. et al. Selection events operating at various stages in B-cell development. Curr Opin Immunol 2001;13:202—7.5. Torlakovic E., Torlakovic G., Nguyen P.L. et al. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol 2002;26:1343—50.Torlakovic E., Torlakovic G., Nguyen P.L. et al. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol 2002;26:1343—50.6. Staudt L.M., Dent A.L., Shaffer A.L. et al. Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6. Int Rev Immunol 1999;18: 381—403.Staudt L.M., Dent A.L., Shaffer A.L. et al. Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6. Int Rev Immunol 1999;18: 381—403.7. Winter J.N., Gascoyne R.D., Besien K.V. Low-grade lymphoma. Am Soc Hematol Educ Program Hematology 2004;:203—20.Winter J.N., Gascoyne R.D., Besien K.V. Low-grade lymphoma. Am Soc Hematol Educ Program Hematology 2004;:203—20.8. Bosch F., Jares P., Campo E. et al. PRAD-1/cyclinD1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84(8):2726—32.Bosch F., Jares P., Campo E. et al. PRAD-1/cyclinD1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84(8):2726—32.9. Hans Ch., Weisenburger D., Vose J. et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003;101(6):2363—7.Hans Ch., Weisenburger D., Vose J. et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003;101(6):2363—7.10. Ott G., Katzenberger T., Lohr A. et al. Cytomorphological, immunohistochemical and cytogenetic profiles for follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002;99(10):3806—12.Ott G., Katzenberger T., Lohr A. et al. Cytomorphological, immunohistochemical and cytogenetic profiles for follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002;99(10):3806—12.11. Gaulard Ph., Delsol G., Callat M.-P. et al. Cytogenetic and clinicopathologic features of B-cell lymphomas associated with the Burkitt translocation t(14;18)(q24;q32) or its variants. Ann Oncol 2002;13(Suppl 2):33.Gaulard Ph., Delsol G., Callat M.-P. et al. Cytogenetic and clinicopathologic features of B-cell lymphomas associated with the Burkitt translocation t(14;18)(q24;q32) or its variants. Ann Oncol 2002;13(Suppl 2):33.12. Berger F., Traverse-Glehen A., Felman P. et al. Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity? Clin Lymphoma 2005;5(4):220—4.Berger F., Traverse-Glehen A., Felman P. et al. Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity? Clin Lymphoma 2005;5(4):220—4.13. Shlette E., Fu K., Medeoros G. CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases. Hematopathology 2003;120:760—6.Shlette E., Fu K., Medeoros G. CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases. Hematopathology 2003;120:760—6.14. Hummel M., Bentink S., Berger H. et al. A biological definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Eng J Med 2006;354:2419—30.Hummel M., Bentink S., Berger H. et al. A biological definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Eng J Med 2006;354:2419—30.15. Muller-Hermelink H.K., Zettl A., Pfeifer W. et al. Pathology of lymphoma progression. Histopathology 2001;38:285—306.Muller-Hermelink H.K., Zettl A., Pfeifer W. et al. Pathology of lymphoma progression. Histopathology 2001;38:285—306.16. Berglund M., Thunberg U., Amini R.M. et al. Evaluation of immunophenotype in diffuse B-cell lymphoma and its impact on prognosis. Mod Pathol 2005;18:1113—20.Berglund M., Thunberg U., Amini R.M. et al. Evaluation of immunophenotype in diffuse B-cell lymphoma and its impact on prognosis. Mod Pathol 2005;18:1113—20.17. Chang C.-C., McClintock S., Cleveland R. et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28: 464—70.Chang C.-C., McClintock S., Cleveland R. et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28: 464—70.18. Ohshima K., Kawasaki C., Muta H. et al. CD10 and BCL10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001;39:156—62.Ohshima K., Kawasaki C., Muta H. et al. CD10 and BCL10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001;39:156—62.19. Xu Y., McKenna R.W., Doolittle J.E. et al. The t(14;18) in diffuse large B-cell lymphoma correlation with germinal center-associated markers and clonal features. Appl Immunohistochem Mol Morphol 2005;13:111—23.Xu Y., McKenna R.W., Doolittle J.E. et al. The t(14;18) in diffuse large B-cell lymphoma correlation with germinal center-associated markers and clonal features. Appl Immunohistochem Mol Morphol 2005;13:111—23.20. Hermine O., Harionn C., Lepage E. et al. Prognostic significance of bcl-2 protein expression on agressive non-Hodgkin's lymphoma (GELA). Blood 1996;87(1):265—72.Hermine O., Harionn C., Lepage E. et al. Prognostic significance of bcl-2 protein expression on agressive non-Hodgkin's lymphoma (GELA). Blood 1996;87(1):265—72.